EyePoint Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

EYPT$0.36+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Comprehensive Loss

(In thousands except per share data)

	Year Ended	Year Ended
	December 31,	December 31,
	2023	2022
Revenues:
Product sales, net	$14,232	$39,905
License and collaboration agreements	30,797	362
Royalty income	989	1,137
Total revenues	46,018	41,404
Operating expenses:
Cost of sales, excluding amortization of acquired intangible assets	4,632	8,326
Research and development	64,662	49,642
Sales and marketing	11,689	25,507
General and administrative	40,102	34,817
Amortization of acquired intangible assets	—	2,050
Impairment of acquired intangible assets	—	20,699
Total operating expenses	121,085	141,041
Loss from operations	(75,067)	(99,637)
Other income (expense):
Interest and other income, net	6,949	2,131
Interest expense	(1,247)	(3,189)
Loss on extinguishment of debt	(1,347)	(1,559)
Total other income (expense), net	4,355	(2,617)
Net loss before income taxes	$(70,712)	$(102,254)
Provision for income taxes	$(83)	$—
Net loss	$(70,795)	$(102,254)
Net loss per share:
Basic and diluted	$(1.82)	$(2.74)
Weighted average common shares outstanding:
Basic and diluted	38,904	37,317
Net loss	$(70,795)	$(102,254)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities, net of tax of $0 for periods presented	78	(55)
Comprehensive loss	$(70,717)	$(102,309)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.